Justice Rajiv Sahai Endlaw said "same orders" would be passed in respect of the five companies which also included Alembic Pharmaceuticals and Piramal Enterprises Ltd as was passed yesterday and day before in the case of pharma majors Pfizer, Abbott Healthcare and Macleods Pharmaceuticals.
As a result of the court's order, the ban on sale of P&G's Vicks Action 500 extra, Reckitt's D'Cold and Piramal's Saridon have been lifted till March 21.
Alembic has got the relief with respect to its Zeet and Glycodin cough syrups and Wikoryl cold tablet.
For Glenmark, the drugs which would benefit from the order are its Ascoril and Alex cough syrups, Candid ear drops, Candidbiotic, Candid total antifungal cream and Trigulin anti diabetic medicine.
The court asked the counsel for the companies to give the number of years their products have been in the market and listed the matter for further hearing on March 21 when the pleas of Pfizer, Abbott and Macleods would also be taken up.
The companies have sought quashing of the notification on the ground that no show cause notice or hearing was granted to them prior to issuing of the notification.
They have alleged that the notification is silent on the aspect as to which expert committee was appointed by Health Ministry to examine the safety and deficiency of the FDCs.
As per the notification,"On the basis of recommendations of an expert committee, the Central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of said drugs in the country.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
